Study Condition(s): Urothelial Cancer

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Study Alias: JVDC

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02426125 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Participation in this trial could last up to 12 months, depending on how you and your tumor respond
  • Participant must have urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis confirmed by histology or cytology

  • Participant must have disease progression while on a platinum containing regimen in the first-line setting or within 14 months after completing the first-line platinum regimen

  • Participant must not have received more than one prior systemic chemotherapy regimen for metastatic disease

  • Participant must not have received radiation therapy within 4 weeks (≤4 weeks) prior to first dose of study drug or has not recovered from toxic effects of the treatment that was given >4 weeks prior to first dose of study drug

  • Participant must not have a concurrent malignancy or had another malignancy within 5 years (≤5 years) of study enrollment

  • Participant must not have HIV infection or acquired immunodeficiency syndrome-related illness

  • Participant must be willing to provide blood, urine, and tissue samples for research purposes

  • Participant must not be pregnant or lactating

Where to Participate

147 locations are currently available of 150 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.